Oxidative stress and lymphocyte persistence: implications in immunotherapy.

作者: Shikhar Mehrotra , Dimitrios Mougiakakos , C. Christian Johansson , Christina Voelkel‐Johnson , Rolf Kiessling

DOI: 10.1016/S0065-230X(09)02006-5

关键词:

摘要: CD8(+) T cells respond to antigen stimulation through a process of activation, division, and differentiation generating large pool activated effector cytolytic lymphocytes (CTLs). Many cancer patients harbor the accordant precursor CTLs capable responding various tumor-associated antigens (TAA). In selected cases, vaccination with these TAA can elicit detectable antitumor responses. Presently, clinical outcome remains inadequate. The lack efficacy may be attributed molecular cellular mechanisms developed by tumors successfully evade host immune system. Some have been identified. It is becoming increasingly apparent that immunotherapy sole objective inducing activation in itself not sufficient fully overcome averting efficient Strategies neutralize tumor-induced suppression parallel antigenic stimulation. Our data show both oxidative stress- antigen-mediated preferential cell death antigen-experienced memory major contributor dysfunction. persistence functional key element for an response affects any protocol. We therefore propose protecting from premature identifying targeting responsible pathway lead substantial enhancement response. this review, we discuss some fundamental factors involved modulation different lymphocyte subsets towards sensitization or resistance stress.

参考文章(159)
HJ Kolb, J Mittermuller, C Clemm, E Holler, G Ledderose, G Brehm, M Heim, W Wilmanns, Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients Blood. ,vol. 76, pp. 2462- 2465 ,(1990) , 10.1182/BLOOD.V76.12.2462.2462
A.H. Myrset, A. Bostad, N. Jamin, P.N. Lirsac, F. Toma, O.S. Gabrielsen, DNA and redox state induced conformational changes in the DNA-binding domain of the Myb oncoprotein. The EMBO Journal. ,vol. 12, pp. 4625- 4633 ,(1993) , 10.1002/J.1460-2075.1993.TB06151.X
MM Horowitz, RP Gale, PM Sondel, JM Goldman, J Kersey, HJ Kolb, AA Rimm, O Ringden, C Rozman, B Speck, Graft-versus-leukemia reactions after bone marrow transplantation Blood. ,vol. 75, pp. 555- 562 ,(1990) , 10.1182/BLOOD.V75.3.555.555
Aniruddha Choudhury, Szilvia Mosolits, Parviz Kokhaei, Lotta Hansson, Marzia Palma, Håkan Mellstedt, Clinical results of vaccine therapy for cancer: learning from history for improving the future. Advances in Cancer Research. ,vol. 95, pp. 147- 202 ,(2006) , 10.1016/S0065-230X(06)95005-2
Arnon Nagler, L. L. Lanier, S. Cwirla, J. H. Phillips, Comparative studies of human FcRIII-positive and negative natural killer cells. Journal of Immunology. ,vol. 143, pp. 3183- 3191 ,(1989)
Pablo Schierloh, Noemí Yokobori, Mercedes Alemán, Rosa M. Musella, Macarena Beigier-Bompadre, María A. Saab, Leandro Alves, Eduardo Abbate, Silvia S. de la Barrera, María C. Sasiain, Increased Susceptibility to Apoptosis of CD56dimCD16+ NK Cells Induces the Enrichment of IFN-γ-Producing CD56bright Cells in Tuberculous Pleurisy Journal of Immunology. ,vol. 175, pp. 6852- 6860 ,(2005) , 10.4049/JIMMUNOL.175.10.6852
Sergei Kusmartsev, Dmitry I. Gabrilovich, STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion The Journal of Immunology. ,vol. 174, pp. 4880- 4891 ,(2005) , 10.4049/JIMMUNOL.174.8.4880
Sergei Kusmartsev, Yulia Nefedova, Daniel Yoder, Dmitry I. Gabrilovich, Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. Journal of Immunology. ,vol. 172, pp. 989- 999 ,(2004) , 10.4049/JIMMUNOL.172.2.989
Helena Harlin, Mikael Hanson, C. Christian Johansson, Daiju Sakurai, Isabel Poschke, Håkan Norell, Karl-Johan Malmberg, Rolf Kiessling, The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset. Journal of Immunology. ,vol. 179, pp. 4513- 4519 ,(2007) , 10.4049/JIMMUNOL.179.7.4513